Murray DB, McMillan R, Brower GL, Janicki JS. ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats. Am J Physiol Heart Circ Physiol 297: H109 -H116, 2009. First published May 8, 2009 doi:10.1152/ajpheart.00968.2008.-The objective of this study was to investigate the ability of selective endothelin receptor subtype A (ET A) endothelin receptor antagonism (ETA) to prevent the acute myocardial remodeling process secondary to volume overload. Left ventricular tissue from sham-operated (Sham) and untreated (Fist), and TBC-3214 (Fist ϩ ETA, 25 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 )-treated fistula animals was analyzed for mast cell density, matrix metalloproteinase (MMP) activity, and extracellular collagen volume fraction (CVF) 1 and 5 days following the initiation of volume overload. Compared with Fist, ETA treatment prevented the increase in left ventricular mast cell density at 1 day and 5 days. Additionally, at 1 day postfistula, a substantial decrease in MMP-2 activity below Sham levels was observed following endothelin receptor antagonism (1.7 Ϯ 0.7 vs. 0.3 Ϯ 0.3 vs. 0.9 Ϯ 0.2 arbitrary activity units, Fist vs. Fist ϩ ETA vs. Sham, P Յ 0.05). This same effect was also seen at 5 days postfistula (1.9 Ϯ 0.3 vs. 0.5 Ϯ 0.1 arbitrary activity units, Fist vs. Fist ϩ ETA, P Յ 0.05). The marked decrease in myocardial CVF seen in Fist hearts (0.7 Ϯ 0.1 vs. 1.6 Ϯ 0.1% myocardial area, Fist vs. Sham, P Յ 0.05) was prevented by ETA (1.7 Ϯ 0.1% Fist ϩ ETA, P Ͻ 0.05 vs. Fist). This preservation of the collagen matrix was also present on day 5 in the TBC-treated group vs. the Fist group (1.0 Ϯ 0.1 vs. 1.4 Ϯ 0.1%, Fist vs. Fist ϩ ETA, P Յ 0.01). Furthermore, an 8-wk preventative treatment with ETA significantly attenuated the increase in left ventricular end systolic and diastolic volumes compared with untreated fistula hearts. In conclusion, the novel findings of this study indicate that the activation of cardiac mast cells and subsequent MMP activation/collagen degradation during the acute stages of volume overload are prevented by blockade of the ET A receptor subtype. Furthermore, by preventing these events, ET-1 antagonism was efficacious in attenuating ventricular dilatation and limiting the development of structural and functional deficits.
Furthermore, an 8-wk preventative treatment with ETA significantly attenuated the increase in left ventricular end systolic and diastolic volumes compared with untreated fistula hearts. In conclusion, the novel findings of this study indicate that the activation of cardiac mast cells and subsequent MMP activation/collagen degradation during the acute stages of volume overload are prevented by blockade of the ET A receptor subtype. Furthermore, by preventing these events, ET-1 antagonism was efficacious in attenuating ventricular dilatation and limiting the development of structural and functional deficits.
endothelin-1; mast cell; matrix metalloproteinase; TBC-3214 ENDOTHELIN (ET)-1 is a potent neurohormone produced throughout the cardiovascular system, and the observation that plasma ET-1 is elevated in patients with heart failure is suggestive of a role in the pathophysiology of heart failure (16, 19, 34, 40, 47) . The cardiovascular effects of ET-1 (a 21-amino-acid peptide) are dictated by binding to one of two G protein-linked receptor subtypes [endothelin receptor subtypes A (ET A ) or B (ET B )] (23). In the heart and vasculature, binding and activation of ET A is known to mediate powerful vasoconstrictor and pressor affects, in addition to chronotropic and ionotropic effects (12, 25) . The ET B receptor subtype is responsible for systemic clearance of circulating ET-1 and nitric oxide-dependent vasodilatation (4) . Previous studies from our laboratory using the aortocaval fistula model of volume overload established a causal role for cardiac mast cells in the upregulation of matrix metalloproteinase (MMP) activity (7, 13, 14) . The role of MMPs in mediating the degradation of the extracellular matrix leading to ventricular dilatation has been well documented (7, 11, 14, 26, 48) . The observation by Podesser et al. (43) among others demonstrated beneficial effects of ET A receptor antagonism in left ventricular (LV) remodeling in the stressed heart due to decreased MMP activation (3, 41) . Previously, we established that ET-1 was capable of activating cardiac mast cells (37) . Recently, we were able to demonstrate in the aortocaval fistula model that combined ET A /ET B receptor antagonism prevented the acute increase in MMP activity by limiting LV mast cell activation (38) . Therefore, the aim of the present study was to determine the ability of a highly selective ET A antagonist to attenuate the maladaptive changes occurring in the initial phase of ventricular remodeling in the aortocaval fistula model of volume overload. To this end, we evaluated changes in LV mast cell density, MMP activity, extracellular fibrillar collagen concentration, as well as diastolic and systolic function. The results indicate that ET A antagonism was capable of attenuating mast cell-mediated ventricular remodeling by reducing MMP activation responsible for subsequent extracellular matrix degradation. Furthermore, an 8-wk treatment strategy utilizing ET A antagonism initiated at the onset of volume overload was able to prevent adverse ventricular remodeling.
MATERIALS AND METHODS

Animal Welfare
All experiments were performed using 9-wk-old (200 -250 g) male Sprague-Dawley rats housed under standard environmental conditions and maintained on commercial rat chow and tap water ad libitum. All studies conformed to the principles of the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" and were approved by our Institution's Animal Care and Use Committee. Anesthesia for the experimental procedure was affected by pentobarbital sodium (50 mg/kg ip). The selective (ETA) endothelin receptor antagonist, TBC-3214, is a next-generation sitaxsentan that has an IC50 for ETA of 40 pM and is highly selective for ETA vs. ETB (400,000-fold) (54) . TBC-3214 (25 mg/kg body wt; Texas Biotechnology) was dissolved in drinking water, administered 3-5 days before surgery, and continued for the duration of the specific experimental group (i.e., 1 and 5 days or 8 wk postfistula). This dose of TBC-3214 was selected based on the manufacturer's (Texas Biotechnology) specified oral bioavailability concentrations documented in previous in vitro studies (42, 53, 54) . Use of this class of ETA receptor antagonist in heart failure patients was capable of improving pulmonary hemodynamics but did not affect systemic vascular resistance (for review, see Ref. 36a).
Experimental Design
Animal groups. Three separate study periods [1 and 5 days and 8 wk following the creation of an abdominal aorta-inferior vena cava (AV) fistula] were investigated. Sham-operated (Sham), untreated fistula (Fist), and endothelin receptor antagonist TBC-3214-treated fistula (Fist ϩ ETA) groups (n ϭ 6 -8/group) were evaluated at the 1-and 5-day time points to determine whether TBC-3214 treatment could prevent the acute increase in cardiac mast cell density and MMP-2 activation, as well as prevent the myocardial extracellular collagen matrix degradation typical of the initial phase of remodeling in this model (29) . To assess the structural and functional effects of chronic ETA receptor antagonism, Sham, (n ϭ 7), Fist, (n ϭ 13), and Fist ϩ ETA (n ϭ 8) groups were analyzed at 8 wk postsurgery to obtain LV systolic and diastolic pressures and volumes via highfidelity Millar conductance catheterization. TBC-3214-treated shamoperated groups (n ϭ 4 -5/group) were included for each of the individual time points. These time points were chosen based on our previous characterization studies demonstrating 1) significant acute increases in the density of cardiac mast cells, 2) significant increase in MMP activity within 1 day following the creation of an AV fistula, and 3) significant collagen degradation occurring between 3-5 days postfistula producing changes in ventricular morphology. Subsequent to this, the remodeling consists of a return to near-normal mast cell density and collagen values in the myocardium between 7 and 14 days. Concomitant chamber dilatation developing in this initial period of remodeling rapidly stabilizes and does not progress further until beyond 4 -5 wk postfistula (7, 10, 29) . At 8 wk, signs of heart failure begin to appear in ϳ50% of the volume-overload rats.
Infrarenal AV fistula. An infrarenal AV fistula was created in rats as described previously (38, 39) . Briefly, a ventral abdominal laparotomy was performed to expose the aorta and caudal vena cava. Both vessels were temporarily occluded proximal and distal to the intended puncture site, and an 18-gauge needle was inserted in the abdominal aorta ϳ1.5 cm below the renal arteries and advanced through the medial wall into the vena cava. The needle was withdrawn, and the puncture site was sealed with surgical glue. Creation of a successful AV fistula was evident by the pulsatile flow of oxygenated blood in the vena cava.
Assessment of LV volume and function. In vivo LV volume and function was assessed in anesthetized rats using a high-fidelity Millar (SPR-838; Millar Instruments, Houston, TX) conductance catheter inserted in the LV via the right carotid artery at 8 wk postsurgery as previously described (38, 51) . This measurement technique requires that a small amount (0.1 ml) of 15% saline be introduced in the external jugular vein of the anesthetized animal at the end of the experimental protocol as a correction factor for the blood-tissue interface. Data were analyzed using the manufacturer's proprietary software (PVAN 3.5; Millar Instruments). At the experimental endpoint, the atria and great vessels were removed and the LV (plus septum), and the right ventricle (RV) were separated and weighed. Lung wet weight was also obtained after the esophagus and trachea were trimmed away and the pleural surface blotted dry.
Assessment of mast cell density and fibrillar collagen concentration. At the end of the 1-and 5-day experimental periods, a transmural section of LV was taken from the midventricle and placed in buffered formalin. The tissue was then processed for routine histopathology, using sequential 5 m paraffin-embedded sections stained with either pinacyanol erthrosinate for the visualization of mast cell morphology or picrosirius red for quantification of myocardial interstitial collagen volume fraction (CVF), as previously described (13, 37) . Mast cell density was determined from the total number of mast cells per LV cross section normalized for the total myocardial area determined from the digitized image (ImageQuant; Molecular Dynamics). CVF was obtained using a Bio-Rad MRC-1024 confocal laser-scanning microscope with a ϫ40 objective lens magnification. Twenty random fields per slide were digitized, and image analysis was performed using Scion-image software. The pixel counts of highlighted interstitial collagen fibers were expressed as a percentage of the total number of pixels in the field to derive the percent area of collagen. Perivascular collagen was excluded from the analysis. Tissue sections were analyzed in a blinded fashion.
MMP activity. MMP activity in cardiac tissue extracts was analyzed using gelatin zymography performed by standard procedures using a SDS-PAGE matrix containing gelatin (1 mg/ml) (13) . Activity of the bands was quantified by densitometry (ImageQuant; Molecular Dynamics). All of the zymograms were analyzed for bands corresponding to standards for the proenzyme (68 kDa) and activated (62 kDa) forms of gelatinase A (MMP-2) (Chemicon International, Temecula, CA). These zymograms were also analyzed for two bands corresponding to standards for the proenzyme (95 kDa) and activated (82 kDa) forms of MMP-9, however, no differences between groups were noted. The values obtained for MMP activity for each sample were normalized for their protein concentration using a Bio-Rad Protein assay. Each gel was run in duplicate. To compare results from different gels, a single extract from the same control heart was used as a standard on all gels. The activities of the lytic bands in the other lanes of a gel were expressed as a percent of this standard's activity. Once normalized in this fashion, the percentages of activity from hearts belonging to each group (i.e., control and fistula) were averaged.
Western blot analysis. SDS-denatured samples were subjected to electrophoresis in 10% (wt/vol) polyacrylamide gels. Briefly, nitrocellulose membranes containing the material transferred from the polyacrylamide gel were incubated with 3% (wt/vol) gelatin in 0.02 M Tris, pH 7.4, and 0.5 M NaCl (TBS) for two 30-min periods to block any nonspecific reactivity. Appropriate dilutions of monoclonal or polyclonal antibody [MMP-13, MMP-2, and tissue inhibitor of metalloproteinase-1 (TIMP); Cambridge and Santa Cruz] were applied and incubated overnight at room temperature. Excess antibody was removed by sequentially washing the membranes in TBS containing 3% gelatin and then incubated with alkaline phosphatase-conjugated goat anti-mouse IgG at room temperature for 2 h. After the second antibody step, membranes were sequentially washed and developed with enhanced chemiluminescense (Amersham) and exposure to hyperfilm (Kodak). The membrane was then stripped and reprobed for glyceraldehyde-3-phosphate dehydrogenase. Once normalized in this fashion, the differences in protein expression from hearts belonging to each group (i.e., sham and fistula) were averaged.
Enzyme-linked immunosorbent assay. Levels of ET-1 and tumor necrosis factor (TNF)-␣ in myocardial tissue were analyzed using commercially available kits (Alpco Diagnostics and Quantikine by R & D Systems, respectively). Briefly, precoated wells were treated with assay buffer and 50 l of extracted protein sample for 1 h and washed five times with wash buffer. Wells were then incubated with appropriate monoclonal antibody directed against ET-1 or TNF-␣, followed by horseradish peroxidase-conjugated antibody after washing. They were then read by spectrophotometry at 450 nm, according to the manufacturer's specifications.
Statistical Analysis
Statistical analyses were performed with Graphpad Prism 4.0 (GraphPad Software, San Diego, CA). Statistical difference between drug-treated control groups and the untreated sham-operated groups are reported accordingly. The remaining comparisons are made between untreated and treated fistula groups. All grouped data are expressed as means Ϯ SE unless otherwise noted. Grouped data comparisons were made by one-way ANOVA with intergroup comparisons analyzed using Bonferroni post hoc testing. Statistical significance was taken to be P Յ 0.05.
RESULTS
Mast Cell Density and MMP Activation
We investigated the response of LV mast cells, MMP activity, and extracellular matrix components after 1 and 5 days following the creation of an aortocaval (AV) fistula with and without ET A receptor inhibition. A representative histological section demonstrating the appearance of mast cells in the myocardium from sham and untreated fistula rats is shown in Fig. 1, A and B, respectively. As can be seen, the mast cells in the sham myocardium stain much more intensely than those in the fistula myocardium, indicating a dense granulation. This contrast in staining is due to the fact that several of the fistula mast cells are in the process of degranulating. Depicted in Table 1 are LV mast cell density values that demonstrate a significant increase in the untreated fistula hearts at 1 day postfistula relative to control. ETA treatment prevented this increase in LV mast cell density. At 5 days postfistula, LV mast cell density was still significantly increased in the untreated fistula group compared with control. The changes in mast cell density were also prevented at the 5-day time point with ETA. Figure 2 depicts a substantial inhibition in MMP-2 activation following ET A receptor antagonism with ETA. Not only was the fistula-induced increase in MMP-2 activity (62 kDa) prevented in the ETA-treated group, but MMP-2 activity was further reduced below control levels at both 1 (1.7 Ϯ 0.7 vs. 0.3 Ϯ 0.03) and 5 days postfistula (1.9 Ϯ 0.3 vs. 0.5 Ϯ 0.1 arbitrary activity units; Fist vs. Fist ϩ ETA, respectively, P Յ 0.05). MMP-2 activity in TBC-treated sham-operated hearts trended lower; however, this decrease did not reach the level of significance. Zymographic analysis of MMP-9 active and latent bands indicated no significant changes in overall activity in any of the experimental groups. Additionally, a set of quantitative studies evaluated MMP-2, MMP-13, and TIMP-1 protein expression by Western blot analysis. Figure 3 shows that TIMP-1 expression was not significantly changed from the sham-operated or untreated fist at either 1 or 5 days postsurgery. ETA receptor antagonism did not alter TIMP protein levels compared with untreated fist. There was a modest trend for the latent form of MMP-2 protein to diminish in the untreated fistula groups. ETA receptor antagonism appeared to attenuate this, but neither group's change reached the level of significance.
Extracellular Matrix Content and Composition
Consistent with observed changes in MMP activity, untreated fistula hearts underwent a marked loss of ventricular collagen on day 1 compared with control (1.6 Ϯ 0.1 vs. 0.7 Ϯ 0.1% myocardial tissue; P Յ 0.05), which was also evident at 5 days postfistula (1.6 Ϯ 0.1 vs. 1.0 Ϯ 0.1% myocardial tissue; P Յ 0.05) (Fig. 4) . Administration of selective ET A receptor antagonism prevented the loss of interstitial collagen at 1 day (0.7 Ϯ 0.1 vs. 1.7 Ϯ 0.1% myocardial tissue; Fist vs. Fist ϩ ETA respectively, P Յ 0.01) and 5 days (1.0 Ϯ 0.1 vs. 1.4 Ϯ 0.1% myocardial tissue; Fist vs. Fist ϩ ETA, respectively, P Յ 0.05) (Fig. 2) postfistula.
Neurohormone Cytokine Interaction
We investigated the LV tissue levels of ET-1. Although these levels were significantly elevated (200%) in the untreated fistula compared with control by day 1, ET-1 levels in 5-day untreated fistula hearts were markedly reduced compared with 1-day fistula with values similar to control (Fig. 5) . The presence of ETA prevented the acute increase in ET-1 levels seen in the untreated 1-day fistula group. Additionally, myocardial TNF-␣ levels were significantly elevated by ϳ200% in the untreated fistula at days 1 and 5 compared with the control values (Fig. 6) . Administration of ETA prevented the increase in TNF-␣ levels at both 1 and 5 days postfistula (Fig. 6) .
LV Function
We also investigated the functional outcome of an 8-wk preventative treatment with ETA initiated before the creation of chronic volume overload and continued thereafter. It should be noted that it was necessary to split the untreated fistula group into two separate structural and functional categories according to whether symptomatic heart failure was manifested at the 8-wk time point (28) . Approximately 50% of the untreated rats were designated as being decompensated based on exhibiting at least two of the following three criteria: 1) LV end diastolic volume (EDV) Ͼ550 l, 2) RV mass Ͼ500 mg, and 3) lung mass Ͼ2,750 mg, as previously established (10, 28) .
None of the animals in the TBC-treated group were classified as decompensated.
Our results demonstrated that, while body, LV, and RV weights ( Table 2) were not significantly different between compensated and ETA-treated fistula groups, the systolic performance and diastolic parameters were markedly better in the ETA-treated fistula vs. the decompensated fistula group. gated LV chamber dilatation, as evidenced by a significantly smaller EDV in the ETA-treated group compared with either compensated or decompensated fistula hearts. This was mirrored by a significant reduction in end diastolic pressure as well. The increase in end systolic volume in the untreated fistula group was also prevented by ETA treatment. ETA treatment led to improved stroke volume, ejection fraction, and higher cardiac output compared with decompensated fistula animals. Even though cardiac output and ejection fraction were maintained in the compensated Fist group, this was achieved at the cost of significant LV dilatation. Finally, there were no significant differences between minimum or maximum first derivative of LV pressure with respect to time (dP/dt) between any of the groups.
DISCUSSION
Initially investigated for potent vasoactive properties, evidence for ET-1 involvement in extracellular matrix turnover in disease states has been mounting (1, 2, 21, 38, 46) . Clinical trials using ET A receptor antagonist in congestive heart failure patients reported lower systemic vascular resistance that resulted in higher cardiac index (6, 31) . Beyond this modest hemodynamic effect, no additional benefits were documented. However, it should be noted that these findings were obtained in patients with existing heart failure (New York Heart Association II or higher) after documented alterations in LV structure and function had developed. Unfortunately due to these limited findings, the efficacy of selective endothelin receptor antagonism in attenuating the maladaptive changes in the early stages of ventricular remodeling was never fully investigated. Recently, we were able to show that not only was ET-1 capable of causing cardiac mast cell degranulation and subsequent MMP activation ex vivo but that cardiac mast cell-mediated ventricular remodeling was initiated by the endogenous endothelin system (37, 38) . Accordingly, the current study investigated the effects of selective (ET A ) ET-1 receptor antagonism on the acute myocardial remodeling process associated with sustained ventricular volume overload. Our findings demonstrate that the increase in LV mast cell density and MMP activity and subsequent degradation of myocardial collagen is an ET A receptor-mediated event confirming that the initial myocardial remodeling in response to volume overload is attributable to increases in endogenous ET-1.
Mast Cell Density Postfistula
ETA treatment exerted a significant effect on the acute response in mast cell density in the stressed myocardium, effectively preventing the marked increase seen in the untreated fistula group at 1 and 5 days. These findings are consistent with our recent study using the nonselective endothelin receptor antagonist bosentan, which also prevented the fistula-induced increase in mast cell density. However, the results herein are the first to demonstrate that this effect on cardiac mast cell density is mediated via the ET A receptor subtype.
Metalloproteinase Activation and Collagen Degradation Postfistula
Numerous studies have implicated a direct contribution of MMPs in the pathophysiological dilatation that occurs in the failing heart (29, 49) . A potential connection between ET-1 and MMP induction in pathological disease states has been observed from investigations of tumor cell invasion, cancerous growth, arthritis, and vascular remodeling (1, 2, 5, 45, 46 ). The recent study by Deschamps et al. (17) found ET A selective receptor antagonism attenuated the ET-1-mediated increase in membrane type 1 MMP activity following ischemia-reperfusion. However, this study did not address changes in overall LV function secondary to ET-1-mediated myocardial remodeling. Similarly, work by Podesser et al. (43) yet no particular cell type was implicated. The results herein bridge these earlier reports, demonstrating a causal linkage between ET-1-mediated cardiac mast cell activation and MMP activity. The efficacy of ETA preventing these events demonstrates a clear role for the ET A receptor subtype in producing the acute mast cell-mediated increase in MMP activity. Total myocardial CVF levels in untreated fistula groups at both 1 and 5 days postfistula were significantly decreased as a result of MMP activation. Treatment with ETA prevented this decrease in interstitial collagen, maintaining overall levels of collagen near control values. These results do not reflect changes in collagen types and cross-linking; however, they are consistent with the observations of reduced mast cell density and diminished MMP-2 activation seen in the ETA-treated fistula group.
Neurohormonal Cytokine Axis
Treatment with ETA prevented the increase in myocardial ET-1 levels 1 day following the creation of an AV fistula. In our previous study, myocardial levels of ET-1 were significantly elevated at both 1 and 5 day postfistula in animals treated with the nonselective endothelin receptor antagonist bosentan. However, by 5 days postfistula, ET-1 tissue levels were normal in the untreated and TBC-3214 fistula group. We believe this was due to enzymatic degradation by mast cellderived chymase, as previously reported by Maurer et al. (33) as well as Metsarinne et al. (36) or possibly due to clearance by the ET B receptor.
Previous studies have documented that ET-1 is capable of inducing TNF-␣ expression in mucosal and connective tissue type mast cells (15, 32) . Administration of the dual ET A /ET B receptor antagonist bosentan to sham-operated and fistula animals resulted in elevated TNF-␣ levels. The findings herein indicate that ET A selective antagonism is capable of preventing increased myocardial TNF-␣ expression at both 1 and 5 days postfistula. However, it should be noted that myocardial TNF-␣ is predominantly localized in the mast cell (22, 24) under nonstressed conditions, whereas, for later time points during chronic pathophysiological stress, other mechanisms and sources for TNF-␣ expression exist (30, 35, 44) .
Effect of ET A Receptor Antagonism on Postfistula Remodeling and LV Contractile Function
Volume overload-induced remodeling was associated with increased body, LV, RV, and lung weights compared with sham-operated controls at the 8-wk experimental end point. Conductance catheter data indicate marked dilatation in both the compensated and decompensated fistula groups compared with control heart dimensions. The overall frequency of compensated to decompensated heart failure animals in this model is a near 1:1 ratio at the 8-wk postsurgery time point (8, 28) . In contrast, none of the eight animals in the ETA-treated group developed symptomatic heart failure. Moreover, the adverse ventricular remodeling in both untreated fistula groups (e.g., increased EDV) was prevented by ETA treatment. Systolic function as measured by ejection fraction was markedly better in the ETA-treated fistula group compared with decompensated fistula hearts. The modest elevation in maximum dP/dt observed in compensated and decompensated animals could be related to elevated neurohormonal input from chronic sympathetic stimulation and increased levels of circulating epinephrine/norepinephrine. A recent study by Ding et al. (18) demonstrated that isolated myocytes from hearts 5 wk postfistula were still responsive to adrenergic stimulation. However, isolated myocytes from hearts 10 wk postfistula were unresponsive (lacking a response) to the same adrenergic challenge (18) . Regardless, the extent of chamber dilatation present in the decompensated group in conjunction with the depressed stroke volume, cardiac output, and ejection fraction are indicative of a heart that is beginning to fail. The results from the ETAtreated group indicate that ET A antagonism was beneficial in attenuating ventricular dilatation and thereby limited the development of structural and functional deficits. A possible mechanism by which ET-1 receptor antagonism could mediate effects over cardiac mast cell density or activation is through the reduction of myocardial oxidative stress. In vitro studies have identified reactive oxygen species as an initiator of mast cell cytokine expression and histamine release (50, 52) . Recent work by Gilles et al. (24) demonstrated a role for oxidative stress in mast cell activation in vivo following ischemia and reperfusion. The results from that study indicated corresponding increases in mast cell secretory products (i.e., histamine or tumor necrosis-␣) in response to oxidants perfused through isolated hearts and that mast cell stabilizers blocked this release. More recent reports have demonstrated that treatment of ischemic myocardium with either selective (ET A , BQ-123) or nonselective (ET A -ET B , bosentan) receptor antagonism significantly reduced catalase and superoxide dismutase activity as well as glutathione content (20, 27, 41) . Indeed, our preliminary data (n ϭ 3/group) reveals a significant reduction in the LV tissue levels of malonyl-CoA dehydrogenase at 3 days postsurgery in ETA-treated fistula animals compared with untreated fistula values (791 Ϯ 72 vs. 1,380 Ϯ 168 nM malondialdehyde/wet LV tissue weight, Fist ϩ ETA vs. Fist respectively, P Յ 0.05). However, whether ET-1 receptor antagonism reduces myocardial oxidative stress and thereby prevents resident mast cell stimulation or there is direct ET A receptor-dependent cardiac mast cell activation remains uncertain.
In summary, the increased cardiac mast cell density seen during the acute stages of volume overload is sensitive to endogenous ET-1. ET-1 antagonism was capable of attenuating acute mast cell-mediated adverse remodeling by reducing MMP activation and subsequent extracellular matrix degradation. Furthermore, this process appears to be mediated specifically by the ET A receptor subtype. Consistent with prevention of the acute remodeling events, an 8-wk preventative treatment with ETA resulted in significantly attenuated changes in LV end systolic and diastolic volumes compared with untreated fistula hearts. By preventing the initial remodeling events, ET-1 antagonism was efficacious in attenuating ventricular dilatation and limiting the development of structural and functional deficits.
